Riskpilot← Back to searchSign inGet full accessBiosergen AB
ABActiveOrg 5593041295Fogdevreten 2Activities of head offices · NACE 7010Est. 20210 employees
Revenue 2024
SEK 2,3M
-52% vs 2023
EBITDA margin
-382.1%
+20% vs 2023
Equity ratio
99.4%
Financial strength
Net profit 2024
SEK -16,7M
+46% vs 2023
| Revenue | SEK 2,3M | -52% |
| EBITDA | SEK -8,7M | +20% |
| Net profit | SEK -16,7M | +46% |
| Total assets | SEK 187,3M | +35% |
| Equity | SEK 186,3M | +35% |
| Employees | 0 | — |
Legal name
Biosergen AB
Org number
5593041295
Legal form
Aktiebolag
NACE code
7010 · Activities of head offices
Founded
26 februari 2021
Share capital
SEK 5 871 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av Ljung, Anna Helena Constance Olesen, Tine Kold Firman tecknas av Ljung, Anna Helena Constance i förening med två av ledamöterna Firman tecknas av Olesen, Tine Kold i förening med två av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhet är att direkt och indirekt bedriva forskning, utveckling, kommersialisering, produktion och försäljning av bioteknologi och medicin samt därmed förenlig verksamhet.
Address
Fogdevreten 2
Email
info@biosergen.net
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 590 | 3 508 | 4 725 | 2 268 |
| Staff expenses | — | — | — | — |
| EBITDA | −11 378 | −9 594 | −10 833 | −8 665 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −11 378 | −9 594 | −10 833 | −8 665 |
| Net financials | 320 | −132 885 | −21 983 | −8 391 |
| Profit before tax | −11 058 | −142 478 | −31 064 | −16 708 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −11 058 | −142 478 | −31 064 | −16 708 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 269 725 | 165 198 | 138 839 | 187 326 |
| Equity | 268 765 | 163 405 | 137 638 | 186 290 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 960 | 1 793 | 1 201 | 1 036 |
| Total debt | 960 | 1 793 | 1 201 | 1 036 |
EBITDA margin
-382.1%
This company
15.8%
Market median
-2518% vs market
20212024
Equity ratio
99.4%
This company
38.2%
Market median
+160% vs market
20212024
Return on equity
-9.0%
This company
18.4%
Market median
-149% vs market
20212024
Net profit margin
-736.7%
This company
8.1%
Market median
-9195% vs market
20212024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20212024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TK Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PJ Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biosergen AB (this company)
Biosergen ASBIOSERGEN ASBoard members of Biosergen AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tine Kold Olesen | Chief Executive Officer | 0 companies |
| Peder Møller Andersen | Chief Executive Officer | 0 companies |
| Per Johan Engstam | Chief Auditor | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Anna Helena Constance Ljung | Chairman | 0 companies |
| Henrik Kristian Moltke | Board of Directors | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Mattias Klintemar | Board of Directors | 0 companies |
| Marianne Kock | Board of Directors | 0 companies |
| Achim Kaufhold | Board of Directors | 0 companies |
| Robert Molander | Board of Directors | 0 companies |
| Marco Taglietti | Board of Directors | 0 companies |
| Torsten Rüdiger Goesch | Chairman | 0 companies |